The latest funding rounds, like Rapalogix Health’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New funding rounds, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Industry Trends
See who's moving and how much in your market
No credit card required Weekly funding digest
Rapalogix Health raises $20 million in Series A financing co-led by Woodline Partners and GordonMD Global Investments to enhance longevity-based skin health.
PRIVATEJun 23, 2026•about 9 hours ago
Amount Raised
$20 Million
Round Type
series a
New YorkBiotechnology
Investors
Gordon Md Global Investments LpWoodline Partners
Description
Rapalogix Health, a biotechnology company, has announced a successful closing of a $20 million Series A financing round. The funds will support the commercialization of Re-Q Health™ and advance their pipeline aimed at the biological mechanisms of skin aging. Co-led by Woodline Partners and GordonMD Global Investments LP, this round signifies a major milestone for the company. Founded by experts in longevity science, Rapalogix aims to translate scientific advances into effective skincare products.
Company Information
Company
Rapalogix Health
Location
228 PARK AVE S, SUITE 66643
New York, New York, United States
About
Rapalogix Health is pioneering the next generation of skin health solutions by targeting cellular longevity. Rooted in cutting-edge science and backed by rigorous research, we develop advanced technologies designed to target the root causes of cellular aging, optimize skin health and shift the paradigm of how we perceive skin aging.
New YorkBiotechnology